Tbh, I can't recall when I first came across the distinction. If it was as presented in the preso (as per slide 4) then, yes, you are right. Both represent "opportunities" internally and externally. And. that does make more sense. Cheers
SYC did elaborate (from memory) that at this stage, our OmniCAR clinical trials will incorporate CP-M via Q-Gen supplying our manufacturing requirements. The inference being that once our program with TFS concludes and culminates in the manufacture of our ultimate superior version, then cells for our own CarT trials will naturally come our TFS automated, closed manufacturing runs. The first being (hopefully) late next year from the prototype system.
I hope I've now made sense of it.
PTX Price at posting:
18.5¢ Sentiment: Buy Disclosure: Held
